Trial Profile

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Thyroid cancer
Focus Therapeutic Use

Most Recent Events

18 Dec 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Nov 2025.
16 Feb 2022 Status changed from not yet recruiting to recruiting.
20 Jan 2022 Planned initiation date changed from 1 Nov 2021 to 1 Feb 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com